文献速递临床试验与 GCP真实世界研究与卫生经济

基于接纳承诺疗法与慈悲的干预对乳腺癌女性的疗效与成本效果:两项随机对照试验的研究方案

Efficacy and cost-effectiveness of an ACT and compassion-based intervention for women with breast cancer: study protocol of two randomised controlled trials {1}.
PubMed 文献 · Trials · 2025-01-03

本文报告两项随机对照试验的研究方案,旨在评估优化版Mind项目(整合接纳承诺疗法与慈悲干预)对乳腺癌女性的疗效与成本效果。研究1将参与者按1:1随机分配至Mind项目或支持小组干预,研究2增加常规治疗组并按2:2:1随机分配,干预均为每周1次、共8次的面授或在线小组形式,随访至6个月。

要点

  • 两项随机对照试验评估优化版Mind项目对乳腺癌女性的疗效与成本效果。
  • 研究1为Mind项目对比支持小组干预(1:1),研究2增加常规治疗组(2:2:1)。
  • 主要结局为癌症特异性生活质量,干预每周1次、共8次,随访6个月。

核心结论

  • 预期Mind组在心理社会、生物学和资源使用方面较对照组有更大改善。
  • 结果可能支持Mind项目对乳腺癌患者的潜在益处,并凸显肿瘤学中整合与整体干预的临床相关性。

研究设计与样本

  • 两项随机对照试验,研究对象为确诊乳腺癌的女性。
  • 研究1将参与者按1:1随机分配至Mind项目或支持小组干预(阳性对照)。
  • 研究2增加常规治疗组(非阳性对照),按2:2:1随机分配。
  • 两种干预均以每周1次、共8次的面授或在线小组形式实施。
  • 数据在基线、治疗后和6个月随访时收集,结局评估者对分组分配设盲,统计分析采用意向性治疗原则。

主要发现

  • Mind项目预试验已显示可接受性及改善生活质量和心理健康的初步疗效。
  • 结局包括癌症特异性生活质量(主要结局)、焦虑和抑郁症状、心理灵活性、自我慈悲、健康相关生活质量、资源使用以及干预的可接受性和可行性。
  • 研究1还将纳入与乳腺癌预后和心理健康相关的免疫学和表观遗传学标志物。
  • 将进行意向性治疗分析以及变化调节因素和中介因素分析。

关键数值与推荐

  • 研究1随机分配比例为1:1,研究2为2:2:1。
  • 两种干预均为每周1次、共8次的面授或在线小组形式。
  • 数据收集时间点为基线、治疗后和6个月随访。
  • 主要结局为癌症特异性生活质量。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Breast cancer is the most diagnosed cancer in women worldwide and carries a considerable psychosocial burden. Interventions based on Acceptance and Commitment Therapy (ACT) and compassion-based approaches show promise in improving adjustment and quality of life in people with cancer. The Mind programme is an integrative ACT and compassion-based intervention tailored for women with breast cancer, which aims to prepare women for survivorship by promoting psychological flexibility and self-compassion. A pilot study of the Mind programme has shown acceptability and preliminary efficacy in improving quality of life and psychological health. This paper presents the study protocol of two randomised controlled trials that aim to test the efficacy and cost-effectiveness of an optimised version of the Mind programme in women with breast cancer. METHODS: Participants will be women diagnosed with breast cancer randomly assigned to the Mind programme or a support group intervention (active control) in a 1:1 ratio for study 1, while study 2 includes one more arm (treatment as usual; inactive control) and a 2:2:1 ratio. Both interventions will be delivered weekly via an 8-session face-to-face or online group format. Data will be collected at baseline, post-treatment and 6-month follow-up. The efficacy and cost-effectiveness of the two interventions will be assessed. Treatment outcomes will comprise cancer-specific quality of life (primary outcome), anxiety and depressive symptoms, psychological flexibility, self-compassion, health-related quality of life, resource use, and intervention's acceptability and feasibility. Study 1 will also include immunological and epigenetic markers associated with breast cancer prognosis and mental health. Outcome assessors will be blind to group allocation. Statistical analyses will be conducted using an intention-to-treat approach. Analyses of moderators and mediators of change will also be performed. DISCUSSION: These trials examine the efficacy and cost-effectiveness of an integrative ACT and compassion-based intervention tailored for women with breast cancer. Greater improvements in psychosocial, biological and resource use are expected in the Mind group, when compared to the control group(s). Results will likely support the potential benefits of the Mind programme for breast cancer patients and highlight the clinical relevance of integrative and holistic interventions in oncology. TRIALS REGISTRATION {2A, 2B}: ClinicalTrials.gov NCT05642897 and NCT06212414. Registered on December 8, 2022, and January 18, 2024.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Trindade IA, Soares A, Skvarc D, et al. Efficacy and cost-effectiveness of an ACT and compassion-based intervention for women with breast cancer: study protocol of two randomised controlled trials {1}. Trials. 2025. PMID: 39754194. doi:10.1186/s13063-024-08626-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。